Furthermore, the Kaplan–Meier survival curve of the PC3Mtrpv6-/-+pTRPV6 group was significantly improved under mAb82 treatment, clearly demonstrating the efficiency and value of mAb82 antibody in the treatment of TRPV6-expressing PCa tumors. Here, TRPV6 is linked to posterior cortical atrophy.